Tiansli Bio suspended the listing of the board

On January 8th, Tiansli announced that its subsidiary, Tiansli Biopharmaceutical Co., Ltd., had withdrawn its application for listing of the company.
announced that on August 31, 2020, Tianshili Biopharmaceutical Co., Ltd. submitted to the Shanghai Stock Exchange the Application Report of Tianshili Biopharmaceutical Co., Ltd. for the Initial Public Offering of Shares and listing on the Board of Science and Technology (Shanghai Division (2020) No. 01) and related application documents. Notice of public offering of shares and application for listing on the Board of Science and Technology (No. 223 of the SSE) was received on September 29, 2020 and December 24, 2020, respectively, from the Shanghai Stock Exchange regarding the initial public offering of shares of Tiansli Biopharmaceutical Co., Ltd. and the first and second round of examination and inquiry of the application documents for listing on the Science and Technology Board.
Bio submitted the application document for the withdrawal of the initial public offering of shares and listing on the Board of Science and Technology by Tiansli Biopharmaceutical Co., Ltd.
January 8, 2021, according to the official website of the Shanghai Stock Exchange: "On January 06, 2021, Tiansli Biopharmaceutical Co., Ltd. withdrew its application for listing or the sponsor withdrew its sponsorship.
in accordance with Article 67 (2) of the Audit Rules, the Exchange shall terminate its issuance and listing examination.
announcement said that Tiansli Bio withdrew its listing application mainly taking into account the 2020 annual audit schedule and its own business development, in accordance with the relevant rules of the Shanghai Stock Exchange, decided to suspend the listing work.
is expected to continue to advance IPO-related matters after the completion of its annual audit in 2020.
。